



Date: 08.11.2023

To,
Department of Corporate Services,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Scrip Code: 524748

Dear Sir/Madam,

Sub: Outcome of Board Meeting

Ref: Submission of Unaudited Financial Results for the Quarter and Half Year ended on September 30, 2023 as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulations 30 and 33 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of the Company, at its Meeting held on today, i.e. Wednesday 8th November, 2023, inter alia, considered and approved followings:

1. Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2023 along with the Limited Review Report of the Statutory Auditors.
2. Approved appointment of Mr. Sanjib Dutta as Chief Financial Officer (KMP) of the Company with effect from 08th November, 2023.

Details/disclosures required under Regulation 30 of the SEBI Listing Regulations, read with Schedule III thereto and the SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 ("SEBI Circular"), is enclosed herewith as Annexure.

3. Noting of resignation tendered by Mr. Jayesh Pushpavadan Jani from the post of Chief Financial Officer (KMP) of the Company with effect from 31st October, 2023 (closing business hours). Intimation for resignation is already given to exchange on 31st October, 2023.

REGISTERED OFFICE:

Plot No. 162, G.I.D.C., Nandesari - 391340, Dist. Vadodara (Gujarat) (India)
Tel. (O) 87806 04490 E-Mail: linkpharmacs@gmail.com
CIN: L24230GJ1984PLC007540 Website: www.linkpharmachem.co.in



The meeting of the Board of Directors commenced at 12:00 p.m. and concluded at 03.15 p.m.

Kindly take the same on your record.

Thanking you,

Yours truly,
For Link Pharma Chem Limited

Khushbu Patel
Company Secretary
Membership No.: A65182

REGISTERED OFFICE:

Plot No. 162, G.I.D.C., Nandesari - 391340, Dist. Vadodara (Gujarat) (India)
Tel. (O) 87806 04490 E-Mail: linkpharmacs@gmail.com
CIN: L24230GJ1984PLC007540 Website: www.linkpharmachem.co.in



Link

Pharma Chem Ltd.

ISO-9001 - 2015 - ISO-14001 - 2015

LINK PHARMA CHEM LTD.

CIN : L24230GJ1984PLC007540

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30TH SEPTEMBER, 2023

(Rs in Lakhs)

Sr. No.	Particulars	Quarter ended			Half year Ended		Year ended
		30th September 2023	30th June 2023	30th September 2022	30th September 2023	30th September 2022	31st March 2023
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations	604.98	787.63	846.86	1,392.62	2,010.26	3,875.78
	Other income	(2.56)	30.66	60.75	28.11	(20.36)	(14.73)
	Total Income (A)	602.43	818.29	907.61	1,420.72	1,989.90	3,861.05
2	Expenses:						
	Cost of materials consumed	356.61	210.21	533.65	566.82	1,147.57	2,640.87
	Changes in inventories of finished goods and work-in-progress	(6.61)	345.79	(116.87)	339.18	(47.84)	(504.34)
	Employee benefits expense	131.49	133.21	152.94	264.70	290.37	568.87
	Finance costs	21.79	22.87	14.13	44.66	30.93	76.10
	Depreciation and amortization expense	26.13	25.76	22.77	51.90	45.42	92.28
	Other Expenses	212.13	194.67	183.43	406.79	441.35	898.63
	Total expenses (B)	741.54	932.50	790.05	1,674.05	1,907.80	3,772.41
3	Profit before tax (C) = (A-B)	(139.12)	(114.21)	117.56	(253.33)	82.10	88.63
4	Tax expense:						
	(1) Current tax	-	-	18.90	-	35.17	41.50
	(2) Short/(Excess) Provision of tax relating to earlier Year	0.63	-	-	0.63	-	-
	(3) Deferred tax	(37.63)	(31.92)	2.57	(69.55)	(19.91)	(18.28)
	Total tax expense (D)	(37.00)	(31.92)	21.47	(68.92)	15.27	23.22
5	Profit for the year/period (E) = (C-D)	(102.12)	(82.29)	96.09	(184.41)	66.83	65.42
6	Other Comprehensive Income						
	Items that will not be reclassified to profit or loss						
	Net fair value gain on equity instruments through Other Comprehensive Income	0.05	0.15	0.12	0.20	(0.02)	(0.06)
	Remeasurement (loss) / gain of the defined benefit plan	(3.75)	(3.75)	1.30	(7.50)	2.60	(12.42)
	Income tax effect on above	0.97	0.94	(0.40)	1.91	(0.72)	3.47
	Total other comprehensive income for the year/period, net of tax (F)	(2.73)	(2.67)	1.02	(5.40)	1.86	(9.01)
7	Total comprehensive income for the year/period (Net of Tax) (E+F)	(104.84)	(84.96)	97.11	(189.81)	68.69	56.41
8	Paid up Equity share capital of Rs 10 each	444.06	444.06	444.06	444.06	444.06	444.06
9	Other Equity						1,059.85
10	Earnings per equity share (FV of Rs. 10) (Rs.) Basic and Diluted	(2.30)	(1.85)	2.16	(4.15)	1.51	1.47



J. J. J.

REGISTERED OFFICE :

Plot No. 161, 161/1, 162, G.I.D.C., Nandesari - 391340, Dist. Vadodara (Gujarat) (India)

Tel. (O) 87806 04490 E-Mail : linkpharmalimited@gmail.com

CIN: L24230GJ1984PLC007540 WEBSITE : WWW.LINKPHARMACHEM.CO.IN



Link

Pharma Chem Ltd.

ISO-9001 - 2015 - ISO-14001 - 2015

Notes:

- 1 The above unaudited financial results for the quarter and half year ended September 30, 2023 have been duly reviewed by Statutory auditors, recommended by the Audit Committee and have been approved and were taken on record by the Board of Directors at its meeting held on November 8th, 2023.
- 2 The Company's operations fall under single segment namely "Manufacture and Sale of Chemicals".
- 3 As per the Ind AS 109 - 'Financial Instruments', the investment of the Company are valued at market prices and the difference between the cost and market value of the investments are accounted as part of Other Income. The break up of the reported figures are arrived as per working given hereunder.

Particulars	Quarter ended			Half year ended		Year ended
	30th September 2023	30th June 2023	30th September 2022	30th September 2023	30th September 2022	31st March 2023
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Other income (A)	(2.56)	30.66	60.75	28.11	(20.36)	(14.73)
Net Gain/(loss) arising on financial asset designated asat FVTPL (B)	(4.27)	26.43	52.43	22.16	(29.13)	(40.69)
Adjusted Other Income (A-B)	1.71	4.23	8.32	5.94	8.76	25.96

- 4 The figures for the corresponding previous periods have been regrouped/ reclassified wherever considered necessary to confirm to the figures represented in the current period.



Date: November 8th, 2023
Place: Vadodara

For Link Pharma Chem Limited

Satish G. Thakur
Chairman & Whole-time Director
(DIN: 00292129)

REGISTERED OFFICE :

Plot No. 161, 161/1, 162. G.I.D.C., Nandesari - 391340. Dist. Vadodara (Gujarat) (India)
Tel. (O) 87806 04490 E-Mail : linkpharmalimited@gmail.com

CIN: L24230GJ1984PLC007540 WEBSITE: www.linkpharmachem.co.in



Link

Pharma Chem Ltd.

ISO-9001 - 2015 - ISO-14001 - 2015

LINK PHARMA CHEM LTD.

CIN: L24230GJ1984PLC007540

STATEMENT OF ASSETS AND LIABILITIES

(Rs in Lakhs)

Particulars	As at 30th September, 2023	As at 31st March, 2023
	(Unaudited)	(Audited)
I. ASSETS		
1. NON CURRENT ASSETS		
(a) Property, Plant and Equipment	876.30	900.29
(b) Financial Assets		
(i) Investments	254.16	363.87
(ii) Other financial assets	118.30	116.19
(c) Other non-current assets	110.51	110.51
Total non-current assets	1,359.27	1,490.86
2. CURRENT ASSETS		
(a) Inventories	610.41	1,225.00
(b) Financial Assets		
(i) Trade receivables	463.73	362.99
(ii) Cash and cash equivalents	209.35	9.39
(iii) Bank Balances other than (ii) above	11.35	10.42
(iv) Loans	0.99	7.20
(v) Other financial assets	1.84	1.77
(c) Other current assets	71.90	138.17
Total current assets	1,369.57	1,754.94
Total Assets	2,728.84	3,245.80
II. EQUITY AND LIABILITIES		
Equity		
(a) Equity Share capital	444.06	444.06
(b) Other Equity	870.03	1,059.85
Total Equity	1,314.09	1,503.91
Liabilities		
Non-current liabilities		
(a) Financial liabilities		
Borrowings	130.29	198.01
(b) Provisions	33.95	20.15
(c) Deferred tax liabilities (Net)	0.84	72.29
Total non-current liabilities	165.08	290.45
Current liabilities		
(a) Financial liabilities		
(i) Borrowings	760.00	677.67
(ii) Trade payables		
(A) Total outstanding dues of Micro enterprises and Small Enterprises	77.57	40.12
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	299.39	620.53
(iii) Other financial liabilities	9.16	6.23
(b) Other current liabilities	76.11	74.06
(c) Short term Provision	27.45	18.30
(d) Current tax liabilities (Net)	-	14.53
Total current liabilities	1,249.68	1,451.45
Total Equity and liabilities	2,728.84	3,245.80

Date: November 8th, 2023
Place: Vadodara



For Link Pharma Chem Limited

Satish G. Thakur
Satish G. Thakur
Chairman & Whole-time Director
(DIN: 00292129)

REGISTERED OFFICE :

Plot No. 161, 161/1, 162, G.I.D.C., Nandesari - 391340, Dist. Vadodara (Gujarat) (India)

Tel. (O) 87806 04490 E-Mail : linkpharmalimited@gmail.com

CIN : L24230 GJ 1984PLC 007540

WEBSITE : www.linkpharmachem.co.in



Link Pharma Chem Ltd.

ISO-9001 - 2015 - ISO-14001 - 2015

LINK PHARMA CHEM LTD.

CIN : L24230GJ1984PLC007540

STATEMENT OF AUDITED CASH FLOW FOR THE HALF YEAR ENDED 30 SEPTEMBER, 2023

Particulars	For the Half year ended Sept. 30, 2023	For the Half year ended Sept. 30, 2022	For the year ended March 31, 2023
	(Unaudited)	(Unaudited)	(Audited)
A. Cash Flow From Operating Activities			
Net profit before taxation	(253.33)	82.10	88.63
Adjustments For:			
Depreciation and amortization expense	51.90	45.42	92.28
Net gain on sale of investments	(0.18)	(7.45)	(14.63)
Fair valuation of Investments through FVTPL	(22.16)	29.13	40.69
Fair valuation of Investments through FVTOCI	0.20	(0.02)	(0.06)
Remeasurement (loss) / gain of the defined benefit plan	(7.50)	2.60	(12.42)
Bad debts written off	(3.76)	-	39.52
Provision for Doubtful Debts	(4.00)	-	2.00
Dividend Income	(1.18)	-	(8.08)
Interest income	(4.09)	(0.18)	(3.25)
Finance cost	44.66	30.93	76.10
Net Adjustments	53.88	100.44	212.15
Operating Profit Before Working Capital Changes	(199.44)	182.53	300.78
Adjustments For :			
(Increase)/Decrease in inventories	614.59	(122.43)	(749.28)
(Increase)/Decrease in trade receivables	(92.98)	(151.88)	132.00
(Increase)/Decrease in financial assets	6.00	8.53	(0.11)
(Increase)/Decrease in other assets	76.74	177.44	109.51
Increase/(Decrease) in trade and other payables	(255.77)	(40.89)	76.98
Working Capital Changes	348.58	(129.23)	(430.91)
Cash Generated From Operations	149.14	53.30	(130.13)
Taxes Paid (Net)	(25.43)	(28.93)	(40.62)
Net Cash From Operating Activities (A)	123.71	24.37	(170.74)
B. Cash Flow From Investing Activities			
Purchase of property, plant & equipment	(27.90)	(48.33)	(89.29)
Purchase of investments	(11.88)	(28.51)	(341.90)
Proceeds from sale of investments	143.73	-	403.88
Dividend Income	1.18	-	8.08
(Increase)/Decrease in bank deposits	(2.84)	(107.82)	5.02
Interest received	4.01	0.18	6.76
Net Cash Used in Investing Activities (B)	106.30	(184.48)	(7.44)
C. Cash Flow From Financing Activities			
Proceeds from Long term borrowings	-	53.00	53.00
Repayment of long term borrowings	(103.09)	(73.23)	(136.58)
Proceeds/(repayment) of short term borrowings (Net)	117.70	191.06	320.47
Finance cost paid	(44.66)	(30.93)	(76.10)
Net Cash Used In Financing Activities (C)	(30.05)	139.90	160.79
Net Increase In Cash and Cash Equivalents (A+B+C)	199.96	(20.22)	(17.40)
Cash and Cash Equivalents at Beginning of Year	9.39	26.79	26.79
Cash and Cash Equivalents at the End of Year	209.35	6.58	9.39

Date: November 8th, 2023
Place: Vadodara



For Link Pharma Chem Limited

Satish G. Thakur

Satish G. Thakur
Chairman & Whole-time Director
(DIN: 00292129)

REGISTERED OFFICE :

Plot No. 161, 161/1, 162, G.I.D.C., Nandesari - 391340, Dist. Vadodara (Gujarat) (India)

Tel. (O) 87806 04490 E-Mail : linkpharmalimited@gmail.com

CIN: L24230GJ1984PLC007540

WEBSITE : linkpharmachem.co.in

Independent Auditor's Review Report on Unaudited Quarterly and year to date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Link Pharma Chem Limited

1. We have reviewed the accompanying Statement of Unaudited Financial results of Link Pharma Chem Limited ("the Company") for the quarter and half year ended 30th September, 2023 attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

The Nirat, 3rd Floor, 18, Winward Business Park, Behind Emerald One Complex, In the lane of Dr. Prasant Buch's Hospital, Jetalpur, Vadodara 390 007. Tel: +91 265 234 3483

Website: www.cnkindia.com



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited financial results prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which, it is to be disclosed, or that it contains any material misstatement.

For CNK & Associates LLP
Chartered Accountants
Firm Registration No. 101961W/W-100036



Preen Shah

Partner

Membership No. 125011

Place: Vadodara

Date: 8th November, 2023

UDIN: 23125011BGTMTG4840



ANNEXURE

The details/disclosures required under SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 are as below:

Sr. No.	Disclosure Requirement	Details
01.	Reason for change, viz. appointment, resignation, removal, death or otherwise	Appointment of Mr. Sanjib Dutta, as Chief Financial Officer (CFO) and a Key Managerial Personnel (KMP) of the Company.
02.	Date of appointment / cessation (as applicable) & term of appointment	With effect from 08th November, 2023.
03.	Brief profile (in case of appointment)	Mr. Sanjib Dutta is Commerce Graduate from Calcutta University, and having 27 Years of Work-Experience in Company Accounts, commercial Part and Statutory Compliances, Banking, Goods and Services Tax etc.
04.	Disclosure of relationships between Directors (in case of appointment of a director)	Mr. Sanjib Dutta is not related to any Directors of the Company

REGISTERED OFFICE:

Plot No. 162, G.I.D.C., Nandesari - 391340, Dist. Vadodara (Gujarat) (India)
Tel. (O) 87806 04490 E-Mail: linkpharmacs@gmail.com
CIN: L24230GJ1984PLC007540 Website: www.linkpharmachem.co.in